Strontium ranelate: a look back at its use for osteoporosis.
BACKGROUND
Osteoporosis is now considered a major health problem in all developed and in most developing (non-African) countries.


METHODS
In this review, we provide an extensive literature survey (MEDLINE, PubMed, Cochrane Controlled Register), for articles dealing with osteoporosis management and/or strontium ranelate, from 1920 to 2010.


RESULTS
The objective is to provide an extensive, unbiased assessment of the available data allowing strontium ranelate to be placed in perspective with other anti-osteoporosis treatments.


CONCLUSIONS
Owing to a positive benefit-to-risk ratio, strontium ranelate may now be considered a first-line treatment in the management of osteoporosis.
University of Liege, Department of Public Health Sciences, Liege, Belgium. jyreginster@ulg.ac.be
Jean-Yves
JY
Reginster
Audrey
A
Neuprez
D000818:Animals; D050071:Bone Density Conservation Agents / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D009942:Organometallic Compounds / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D013876:Thiophenes / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate